A Modest Financial Proposal

Figure 1The pace, direction, and application of scientific research are largely determined by the availability of money. At an individual level, grant applications consume a great deal of professional time; and gossip about funding successes and failures, along with speculation about donor intentions, fuels hope or opens the door to despair. Yet despite the importance of money, many scientists seem to be as shy about mentioning it in public as our Victorian ancestors were in talking about sex.Ov

Written byMalcolm Potts
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

The pace, direction, and application of scientific research are largely determined by the availability of money. At an individual level, grant applications consume a great deal of professional time; and gossip about funding successes and failures, along with speculation about donor intentions, fuels hope or opens the door to despair. Yet despite the importance of money, many scientists seem to be as shy about mentioning it in public as our Victorian ancestors were in talking about sex.

Over the past decade, more and more journals have begun to demand that authors declare any possible conflicts of interest, such as owning stock in the company that finances the research. Such declarations are useful, but I want to suggest that journals require a second statement: How much did the work cost?

At a minimum, we are likely to be interested in knowing what our colleague's research cost to complete, but the need ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies